Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)
Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
9 July 2025
Gilde Healthcare’s private equity fund combines Artinis and NIRx into a world-leading neuroimaging group
Gilde Healthcare today announces the combined private equity investments in Artinis Medical Systems (Netherlands) and NIRx Medical Technologies (Germany/United States), both pioneers in functional Near-Infrared Spectroscopy (fNIRS) solutions. This dual...
8 July 2025
Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)
Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
9 July 2025
Filter & search
Fund strategy:
Loading...
These were all articles
a2c4a0239f